Coumadin and Samsca drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Coumadin (warfarin sodium) and Samsca (tolvaptan). Common drug interactions include oedema peripheral among females and blood sodium decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Coumadin and Samsca. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Coumadin?

Coumadin has active ingredients of warfarin sodium. It is often used in blood clots. eHealthMe is studying from 133,228 Coumadin users. Check the latest studies of Coumadin.

What is Samsca?

Samsca has active ingredients of tolvaptan. eHealthMe is studying from 8,139 Samsca users. Check the latest studies of Samsca.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 31, 2026

16 people who take Coumadin and Samsca together, and have interactions are studied.

Coumadin and Samsca drug interactions.

What are the common drug interactions of Coumadin and Samsca, by gender? *:

female:

  1. Oedema peripheral (superficial swelling)
  2. Cellulitis (infection under the skin)
  3. Femur fracture
  4. Weight decreased
  5. Blood sodium decreased
  6. Fluid retention (an abnormal accumulation of fluid in the blood)
  7. Oxygen saturation decreased
  8. Angina pectoris (chest pain due to ischemia of the heart muscle)
  9. Arterial occlusive disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked)
  10. Cardiac failure

male:

  1. Blood sodium decreased
  2. Confusional state
  3. Inappropriate antidiuretic hormone secretion
  4. Renal impairment (severely reduced kidney function)
  5. Acute hepatic failure
  6. Acute respiratory failure
  7. Cardiac arrest
  8. Cardiac disorder
  9. Cardiac failure
  10. Cardiac failure congestive

What are the common drug interactions of Coumadin and Samsca, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Cardiac failure
  2. Hepatic enzyme increased

40-49:

n/a

50-59:

  1. Confusional state
  2. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  3. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  4. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  5. Syncope (loss of consciousness with an inability to maintain postural tone)
  6. Alcohol induced persisting dementia
  7. Inappropriate antidiuretic hormone secretion

60+:

  1. Oedema peripheral (superficial swelling)
  2. Blood sodium decreased
  3. Arterial occlusive disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked)
  4. Cardiac arrest
  5. Cardiac disorder
  6. Cardiac failure
  7. Confusional state
  8. Contusion (a type of hematoma of tissue in which capillaries)
  9. Depression
  10. Eating disorder

What are the existing conditions these people have? *

  1. Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 7 people, 43.75%
  2. Blood Sodium Decreased: 3 people, 18.75%
  3. Fluid Retention (an abnormal accumulation of fluid in the blood): 3 people, 18.75%
  4. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 12.50%
  5. Stress And Anxiety: 1 person, 6.25%
  6. High Blood Pressure: 1 person, 6.25%
  7. Cardiac Failure Congestive: 1 person, 6.25%
  8. Diabetes: 1 person, 6.25%
  9. Essential Hypertension (primary hypertension): 1 person, 6.25%
  10. Fungal Nail Infection: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Coumadin and Samsca?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Coumadin and Samsca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Coumadin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Samsca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Coumadin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Samsca and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on warfarin sodium and tolvaptan (the active ingredients of Coumadin and Samsca, respectively), and Coumadin and Samsca (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: